Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Approval alert: NMPA approves Koselugo® (selumetinib) for plexiform neurofibromas in paediatric patients

May 8, 2023

AstraZeneca announced Koselugo® (selumetinib) has been approved in by the Chinese NMPA for the treatment of symptomatic, inoperable plexiform neurofibromas in patients with neurofibromatosis type 1 aged three years and above.  The NMPA relied on results of the SPRINT Stratum 1 trial, published in the New England Journal of Medicine.  The study was sponsored by the National Institutes of Health’s National Cancer Institute Cancer Therapy Evaluation Program.